-
The news of the listing of hypoglycemic drugs continues, and the reshuffle of the diabetes market will accelerate!
Time of Update: 2022-04-15
With the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years .
-
32 senior executives of pharmaceutical companies resigned due to personal reasons, the industry: or affected by the expansion of centralized procurement
Time of Update: 2022-04-15
issued the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally Organized Centralized Purchase of Drugs", requiring medical institutions to start reporting volumes on January 26, and at 24:24 on February 16: Submit data before 00 .
-
WuXi PharmaTech's annual report was outstanding, with a 72% increase in net profit!
Time of Update: 2022-04-15
According to its annual report data, WuXi AppTec achieved a year-on-year increase of more than 72% in net profit in 2021 .
In addition to WuXi PharmaTech, the industry said that companies such as YaoShi Technology, Tigermed, and Proton are worthy of attention as potential CXO stocks .
-
Longshen Rongfa, Jiaying Pharmaceutical and many other traditional Chinese medicine stocks rose
Time of Update: 2022-04-15
The R&D analyst of Southwest Securities also pointed out that the policies of the traditional Chinese medicine industry have continued, and the immune attributes of traditional Chinese medicine consumer goods medical insurance are prominent .
-
The trend of medicine continues to be optimistic, and the net profit of a pharmaceutical company has soared nearly 19 times
Time of Update: 2022-04-15
372 billion yuan; net profit attributable to shareholders of the parent company increased by 1856.
092 billion yuan in 2021; the net profit attributable to shareholders of the listed company has increased by 1312.
-
The net worth of several pharmaceutical securities investment funds rose
Time of Update: 2022-04-15
[Pharmaceutical Network Pharmaceutical Stock Market] On March 23, the net value of a number of pharmaceutical securities investment funds rose, including Huatai Pineapple Biomedical Mixed C, Southern Pharmaceutical Innovation Stock A, E Fund Biomedical Biostock A, Fuguo Biomedical Technology Mixed C, Galaxy Medicine Mixed, Cinda Australia Silver Medicine and Health Mix, etc.
-
Domestic medical device innovation is accelerating, but these aspects still need to be improved
Time of Update: 2022-04-15
Two innovative medical device products, the "Digestive Tract Vibrating Capsule System" produced by the company have been approved for the market .
-
This week, 9 new A-share stocks ushered in the subscription wave, and 1 is a pharmaceutical stock
Time of Update: 2022-04-15
[Pharmaceutical Network Pharmaceutical Stock Market] According to the issuance arrangement, this week (March 28-April 1), a total of 9 new shares were declared, namely Guanlong Energy Saving, Puyuan Jingdian, Qifeng Precision Industry, Haichuang Pharmaceutical, Weixin Pharmaceutical Co.
-
With the continuous expansion of the biopharmaceutical market, the domestic substitution of biopharmaceutical equipment will accelerate
Time of Update: 2022-04-15
The biopharmaceutical market continues to expand, and the domestic substitution of biopharmaceutical equipment is accelerating (Photo source: Pharmaceutical Network) Various regions are vigorously developing the biopharmaceutical industry , the province's bio-pharmaceutical industry operating income to achieve the goal of "protecting four and competing for five" .
-
The TCM health service market has broad prospects, and the industry is optimistic about four major directions
Time of Update: 2022-04-15
In the context of centralized procurement, compared with traditional Chinese medicine prescription drugs, because the main sales market of traditional Chinese medicine OTC is in pharmacies, it is expected to avoid the risks of centralized procurement, and the investment value is further highlighted .
-
Since 2022, a large number of medical representatives have been exposed due to violations, the industry: industry compliance is imperative
Time of Update: 2022-04-15
At the same time, it is clearly stated that if the medical representative violates the relevant regulations, the company's application shall be included in the bad record of commercial bribery in the field of pharmaceutical purchase and sales in Jiangxi Province.
-
Another year of "315", are the pharmaceutical machine companies still on pins and needles?
Time of Update: 2022-04-15
However, compared with imported equipment, domestic pharmaceutical machine companies still need to continue to increase investment in research and development, improve the level of innovation, quality, and after-sales service, etc.
-
The demand for equipment in the pharmaceutical industry continues to increase, and the high-end pharmaceutical machine market will become the focus of the industry
Time of Update: 2022-04-15
According to data, in the process of accelerating the upgrading of the pharmaceutical equipment industry, the growth rate of China's high-end pharmaceutical equipment market is accelerating.
-
Another batch of large-variety drug price cuts!
Time of Update: 2022-04-15
For example, on February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions .
34 drugs produced by 28 pharmaceutical companies ushered in price reductions.
-
The performance of the traditional Chinese medicine sector is still dazzling, with many stocks up more than 3%
Time of Update: 2022-04-15
[Pharmaceutical Network Pharmaceutical Stock Market] On February 10, the overall performance of the traditional Chinese medicine sector was still bright .
In addition to Taiji Group, Jianmin Group, Qianjin Pharmaceutical, Kangenbei and many other stocks all rose more than 3% .
-
Accelerating development with artificial intelligence is emerging in the pharmaceutical industry
Time of Update: 2022-04-15
With the help of artificial intelligence to accelerate development, it is emerging in the pharmaceutical industry (picture source: Pharmaceutical Network) It is understood that due to the long time, high cost, low success rate of research and development, long payback period, and high risk of new drug research and development; With the continuous development of science and technology, more and more companies and researchers have begun to apply "artificial intelligence" to pharmaceutical R&D and marketing .
-
The performance of the traditional Chinese medicine sector is still active, with more than 10 shares trading at the daily limit, and 1 share 5 consecutive boards
Time of Update: 2022-04-15
[Pharmaceutical Network Pharmaceutical Stock Market] On March 31, A-shares opened lower and fluctuated overall in early trading, but the traditional Chinese medicine sector remained active.
6 billion yuan; Zhendong Pharmaceutical opened the daily limit, and the current price is 12.
-
This year, a large number of drugs will be transferred out of medical insurance
Time of Update: 2022-04-15
For example, the "Announcement on Chongqing Municipality's Gradual Digestion of the List of Locally Supplemented Medical Insurance Class B Drugs" issued by the Chongqing Municipal Medical Insurance Bureau stipulates that the real estate drugs with purchased data and those produced and sold by local pharmaceutical companies and whose sales ratio exceeds 20% in Chongqing Other non-property drugs are included in the final year of digestion .
-
The new pharmaceutical shares listed on the Science and Technology Innovation Board have been losing money for four consecutive years!
Time of Update: 2022-04-15
For example, in the domestic NMIBC field, in addition to Asieris' APL-1202, there are 6 innovative drugs of other companies in clinical stage; In the field of HSIL treatment, there are also 3 domestic therapeutic drugs targeting HSIL or CIN2/3 that have entered clinical trials .
-
Is there an opportunity for a strong layout in medicine?
Time of Update: 2022-04-15
As a representative of the CRO (pharmaceutical R&D contract outsourcing service organization) industry, the operating performance of Zhaoyan New Drug, a listed company, continued to rise sharply .
